Skip to main content
. 2023 Oct 26;8(2):378–387. doi: 10.1182/bloodadvances.2023010693

Table 3.

Response and minimal residual disease status during the 12-cycle treatment and follow-up

Clinical response Cycle 3
N = 45
Cycle 7
N = 41
Cycle 12
N = 40
Best response
N = 45
Overall response, % 78 100 98 100
CR(u)/CRi, % 2 15 38 42
PR, % 76 85 60 58
MRD response Cycle 12∗
Cycle 18
Cycle 24
Peripheral Blood
N = 42
Bone marrow
N = 39
Peripheral Blood
N = 29 N = 25
Detectable >10−2, % 2 2
Detectable 10−4 to 10−2, % 31 21 10 4
Undetectable <10−4, % 67 77 90 96

CR, complete repsonse; CRu, unconfirmed CR because of absence of confirmatory bone marrow biopsy; CRi, CR with incomplete hematologic recovery; PR, partial response.

Forty patients had clinical response available at cycle 12 and 42 had MRD assessments at cycle 12.

One patient had PR at cycle 7 and progressive disease at cycle 12.

Cycle 3 and cycle 7 CRs are CRu.